Human Microbiome Market is forecasted to reach USD 2,555 Million by 2030, demonstrating a robust CAGR of 35.8 Percentage | (Viome Life Sciences, Inc., BIOHM Health, DayTwo) - published by MarketDigits

Human Microbiome Market Scope:
Market size value in 2023 - USD 300 Million
Market size value in 2030 - USD 2,555 Million
CAGR (2023-2030) - 35.8%
Forecast Period - 2023-2030
Segments Covered - Product, Type, Disease, Application and Region.
Geographies Covered - North America, Europe, Asia Pacific, and Row
Sample of Companies Covered - Atlas Biomed, Bione Ventures Private Limited, Luxia Scientific, Metabiomics, Sun Genomics, Seed Health, Gnubiotics Sciences.

Download Sample Pages-https://www.marketdigits.com/request/sample/3619

Browse in-depth TOC on "Human Microbiome Market"
178-Tables
95-Figures
332-Pages

The market for Human Microbiome is dominated by North America.
North America stands as the dominating region in the Human Microbiome Market, with several factors contributing to its prominence in this rapidly advancing field. The robust dominance of North America is primarily attributed to the region's strong foundation of healthcare facilities and infrastructure, providing a conducive environment for the exploration and application of microbiome research in medical practices. The United States and Canada, in particular, boast a comprehensive network of healthcare institutions, research centers, and academic facilities that form a solid foundation for pioneering developments in the field of human microbiome studies.
Additionally, the region's position at the forefront of technological innovation plays a pivotal role in its dominance in the Human Microbiome Market. The availability and adoption of advanced devices and cutting-edge technologies for microbiome research contribute significantly to the region's leadership. The United States, being a global hub for biotechnology and pharmaceutical research, attracts substantial investments from key players in the industry. This influx of investments fuels the growth of advanced devices and technologies, positioning North America at the forefront of microbiome-related advancements.

Ask for Discount- https://www.marketdigits.com/request/discount/3619

Top Key Players Covered in the Report-
Therapeutics, Inc., Enterome, 4D pharma plc, International Flavors & Fragrances Inc., OptiBiotix Health Plc, Ferring Pharmaceuticals, Synlogic, Inc., Second Genome, Inc., Vedanta Biosciences, Inc., YSOPIA Bioscience, FlightPath Biosciences, Inc., Finch Therapeutics Group, Inc., AOBiome Therapeutics, BioGaia, Quantbiome, Inc. (dba Ombre), Viome Life Sciences, Inc., BIOHM Health, DayTwo, Atlas Biomed, Bione Ventures Private Limited, Luxia Scientific, Metabiomics, Sun Genomics, Seed Health, Gnubiotics Sciences and Others.

For More Information - Inquire Now!
https://www.marketdigits.com/request/enquiry-before-buying/3619

Recent Developments-
• In September 2021, PhenoBiome today launched a human gut microbiome assay through Genetic Direction, which will process the assays in its CLIA- and CAP-certified laboratory.
• In June 2021, NovoBiome, a drug discovery company has notified that they are building NovoSift, a disruptive ex-vivo research and discovery platform which will analyze the symbiotic relationship between the microbiota and the human intestine.

https://www.globenewswire.com/news-release/2023/11/20/2783139/0/en/Human-Microbiome-Market-projected-to-reach-USD-2-555-Million-by-2030-growing-at-a-CAGR-of-35-8-during-the-forecast-period-of-2023-2030-pronounced-by-MarketDigits-in-its-recent-stud.html

MarketDigits
Email: sales@marketdigits.com

MarketDigits is one of the leading business research and consulting companies that helps clients to tap new and emerging opportunities and revenue areas, thereby assisting them in operational and strategic decision-making. We at MarketDigits believe that a market is a small place and an interface between the supplier and the consumer, thus our focus remains mainly on business research that includes the entire value chain and not only the markets.

This release was published on openPR.